After completing this activity, the participant should be better able to:

• Describe the alterations in cytogenetic, molecular abnormalities, NOTCH1, CRLF2 mutations, epigenetic markers in the diagnosis and treatment of patients with acute lymphoblastic leukemia (ALL)
• Identify the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with ALL
• Assess the prognostic markers, risk stratification and their impact on clinical practice of patients with chronic lymphocytic lymphoma (CLL)
• Identify and apply individualized treatment strategies based on current and emerging novel therapies for CLL
• Describe the alterations in driver mutations revealing molecular subgroups leading to disease classification and prognostic stratification in acute myeloid leukemia (AML)
• Recognize how compound genotypes are related to clinical outcomes in AML patients treated with novel agents
• Evaluate the first line therapy options for chronic myeloid leukemia (CML) in chronic phase
• Identify response assessment and management of tyrosine kinase inhibitors resistance in the treatment of CML
• Recognize the time-based response milestones and monitoring in patients with CML